pertuzumab + trastuzumab + hyaluronidase-zzxf

**Pertuzumab + trastuzumab + hyaluronidase-zzxf** is a fixed-dose subcutaneous biologic combination marketed as **Phesgo**. It contains the anti-HER2 humanized monoclonal antibodies pertuzumab and trastuzumab plus recombinant human hyaluronidase PH20, hyaluronidase-zzxf. Pertuzumab and trastuzumab bind distinct extracellular epitopes of human epidermal growth factor receptor 2, jointly inhibiting HER2 signaling and promoting immune-mediated elimination of HER2-overexpressing tumor cells; hyaluronidase transiently depolymerizes subcutaneous hyaluronan to facilitate dispersion and absorption of the antibodies. In the United States, it is approved with chemotherapy for specified HER2-positive early breast cancer settings and with docetaxel for first-line HER2-positive metastatic breast cancer. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761170s007lbl.pdf))

Brand names

Phesgo

Other names

PH FDC SCpertuzumab + trastuzumab + hyaluronidasepertuzumab + trastuzumab fixed-dose combinationpertuzumab + trastuzumab fixed-dose combination for subcutaneous injectionpertuzumab, trastuzumab, and hyaluronidase-zzxf